Approval · Notice of Compliance 12355 · 2011
PLAVIX: Notice of Compliance 12355
Issued May 17, 2011
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 12355
- Date
- May 17, 2011
- Company
- Sanofi-Aventis Canada Inc.Toronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Revisions to the Product Monograph: Drug-drug interaction with proton pump inhibitors
- Therapeutic class
- Platelet aggregation inhibitor
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PLAVIX | Not yet assigned | — |
Medicinal ingredients
- CLOPIDOGREL BISULFATE 75 MG per TAB
- CLOPIDOGREL BISULFATE 300 MG per TAB